



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Yasuhiro Sasaki et al.

Application No.: 10/019,743

Confirmation No.: 7360

Filed: December 28, 2001

Art Unit: 1653

For:

PROCESS FOR PREPARING LH-RH

Examiner: A. U. Desai

DERIVATIVES

## **INFORMATION DISCLOSURE STATEMENT (IDS)**

MS RCE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the materials listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement, pursuant to 37 CFR 1.114(c), accompanies the Request for Continued Examination (37 CFR 1.114) submitted herewith.

The cited material depicts a comparison of the process claimed in the instant application and process used by Amgen, Incl.

Application No.: 10/019,743 2 Docket No.: 56778(70820)

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 04-1105, under Order No. 56778(70820). A duplicate copy of this paper is enclosed.

Dated: April 28, 2006

Respectfully submitte

Jonathan M. Bparke, PhD. Registration No. 53,624

EDWARDS ANGELL PALMER & DODGE

LLP

P.O. Box 55874

Boston, Massachusetts 02205

(617) 439-4444

Attorneys/Agents For Applicant

PTO/SB/08a/b (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

duction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449A/B/PTO Application Number 10/019,743-Conf. #7360 INFORMATION DISCLOSURE Filing Date December 28, 2001 STATEMENT BY APPLICANT First Named Inventor Yasuhiro Sasaki Art Unit 1653 (Use as many sheets as necessary) Examiner Name A. U. Desai 56778(70820) Sheet 1 1 Attorney Docket Number

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2</sup> ( if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Foreign Patent Document  Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	۳⁵	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patient Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. See Kinds Codes of USPTO Patient Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. See Kinds Codes of USPTO Patient Documents, by the two-letter code (WIPO Standard ST.3). For Japanese patient documents, the indication of the year of the reign of the Emperor must precede the serial number of the patient document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No.1	magazine igurnal serial symnosium catalog etc.) date nagelsi yollime-issue numberisi nunisner			
	CA	Comparison of Takeda & Abbott Production Processes (2 pages)			
	СВ	Comparison of Takeda & Abbott Final Reaction Step and Purification Step (1 page)			
	CC	Comparison of Takeda & Abbott Purification Conditions by Chromatography (1 page)			
	CD	Detailed Abbott Process Steps – Step III B (3 pages)			
	CE	Detailed Abbott Process Steps – Step VIII (1 page)			
	CF	Detailed Abbott Process Steps – Step IX (1 page)			
	CG	Detailed Abbott Process Steps – Step XI (3 pages)			

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	Date		
Signature	Cons	sidered	
540040			

<sup>&#</sup>x27;Applicant's unique citation designation number (optional). 'Applicant is to place a check mark here if English language Translation is attached.